THE MEDICINES PATENT POOL

EXPANDING ACCESS TO PUBLIC HEALTH
The MPP was founded by Unitaid in 2010.

We work with a range of partners — civil society, international organisations, industry, patient groups and governments — to prioritise and license novel and existing medicines and health technologies for people in these countries.

**Mission**
Increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through voluntary licensing and patent pooling.

**Vision**
A world in which people in need in LMICs have rapid access to effective and affordable medical treatments and health technologies.
The MPP negotiates public-health driven licences with patent holders.

The MPP sublicenses drugs to generic companies. Licensing terms encourage the sale of affordable generic versions in developing countries and the development of combinations needed in resource-limited settings.

Royalties where appropriate.
MPP IMPACT ANALYSIS: HIV (2012-2018)

June 2019
Cumulative Patient-Years of HIV Treatment Supplied Through MPP Licensees per Year

Total patient-years (HIV): 21.3 million

*Source: confidential sales data by licensees
Cumulative Patient-Years of HIV Treatment Supplied Through MPP Licensees per Year

Total patient-years (HIV): 21.3 million

*Source: confidential sales data by licensees
Total HIV-related cost-savings by 2018: $883 million
CUMULATIVE PACKS SOLD: TLD & DTG (2012-2018)

CUMULATIVE NUMBER OF PACKS SOLD BY QUARTER (DTG & TLD)

Total number of packs sold: 36.9 million
MPP IMPACT BY HIV PRODUCT (2012-2018)

72% of MPP’s HIV-related impact (cost-savings) is derived from TLE, TLD, & DTG

*TLE: tenofovir disoproxil fumarate (TDF), lamivudine (3TC) & efavirenz (EFV); TLD: tenofovir disoproxil fumarate (TDF), lamivudine (3TC) & dolutegravir (DTG); TE: tenofovir disoproxil fumarate (TDF) & emtricitabine (FTC); TL: tenofovir disoproxil fumarate (TDF) & lamivudine (3TC); TEE: tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) & efavirenz (EFV); ATV/r: atazanavir & ritonavir; LPV/r: lopinavir & ritonavir
TOP COUNTRY RECIPIENTS OF DTG & TLD (2017-2018)

Note: Analysis excludes countries where <5,000 patient-years of treatment were sold

*Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents
TOP COUNTRY RECIPIENTS OF DTG & TLD (2017-2018)

Note: Analysis excludes countries where <60,000 packs of treatment were sold

*Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents
NUMBER OF PEOPLE LIVING WITH HIV

(2018)

Number of People living with HIV (in millions)

*Data source: https://aidsinfo.unaids.org*/
Over 50% of DTG-derived sales are in non-specified SSA countries, South Africa, and Kenya.
DTG & TLD: COUNTRIES OF SALE (2017-2018)

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anguilla</td>
<td>Congo</td>
<td>India</td>
<td>Moldova</td>
<td>Syria</td>
</tr>
<tr>
<td>Argentina</td>
<td>Congo, Dem. Rep.</td>
<td>Iran</td>
<td>Morocco</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Armenia</td>
<td>Cote d’Ivoire</td>
<td>Jamaica</td>
<td>Mozambique</td>
<td>Uganda</td>
</tr>
<tr>
<td>Bahamas</td>
<td>Cuba</td>
<td>Kenya</td>
<td>Myanmar</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Barbados</td>
<td>Dominican Republic</td>
<td>Kyrgyzstan</td>
<td>Namibia</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Egypt</td>
<td>Laos</td>
<td>Nepal</td>
<td>Venezuela</td>
</tr>
<tr>
<td>Botswana</td>
<td>El Salvador</td>
<td>Lebanon</td>
<td>Nigeria</td>
<td>Yemen</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Equatorial Guinea</td>
<td>Lesotho</td>
<td>Pakistan</td>
<td>Zambia</td>
</tr>
<tr>
<td>Burundi</td>
<td>Gabon</td>
<td>Liberia</td>
<td>Paraguay</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Georgia</td>
<td>Madagascar</td>
<td>Rwanda</td>
<td></td>
</tr>
<tr>
<td>Cameroon</td>
<td>Guatemala</td>
<td>Malawi</td>
<td>Saint Lucia</td>
<td></td>
</tr>
<tr>
<td>Cape Verde</td>
<td>Guyana</td>
<td>Mali</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>Haiti</td>
<td>Mauritius</td>
<td>Swaziland</td>
<td></td>
</tr>
</tbody>
</table>

*Analysis include sales of DTG 50mg and TDF/3TC/DTG*